XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets, XenoPort’s internally discovered drug, is approved and being marketed by XenoPort in the United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and is being marketed in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

For more information, please click here For more information, please click here

Mon, 20 May 2013 XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients Fri, 17 May 2013 XenoPort Provides Update on Availability of Horizant   XenoPort Special Conference Call Monday, May 20, 2013 at 8:30 AM ET Webcast CLICK HERE 1-888-275-3514 Toll Free 1-706-679-1417 International Callers The reference number to enter the call and the replay of the call is 74912690.

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including spasticity, Parkinson’s disease and relapsing-remitting multiple sclerosis. Explore the XenoPort Pipeline >